Resverlogix Corp. (RVXCF)
USD 0.03
(-2.79%)
USD 0.03
(-2.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 6.45 Million USD | -8.29% |
| 2021 | 7.03 Million USD | 0.0% |
| 2019 | 13.15 Million USD | 85.66% |
| 2018 | 7.08 Million USD | 1106.81% |
| 2017 | 587 Thousand USD | -98.76% |
| 2016 | 47.28 Million USD | 141.15% |
| 2015 | 19.6 Million USD | -31.27% |
| 2014 | 28.52 Million USD | 10.23% |
| 2013 | 25.87 Million USD | 179.94% |
| 2012 | 9.24 Million USD | 222.24% |
| 2011 | -7.56 Million USD | -58.04% |
| 2010 | -4.78 Million USD | -5.3% |
| 2009 | -4.54 Million USD | 20.16% |
| 2008 | -5.69 Million USD | -158.24% |
| 2007 | 9.77 Million USD | -23.5% |
| 2006 | 12.77 Million USD | 566.67% |
| 2005 | -2.73 Million USD | 58.85% |
| 2004 | -6.65 Million USD | -4172.27% |
| 2003 | -155.72 Thousand USD | 73.3% |
| 2002 | -583.13 Thousand USD | -169.51% |
| 2001 | -216.36 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 6.77 Million USD | 0.0% |
| 2023 Q3 | 6.67 Million USD | -1.42% |
| 2022 Q2 | 6.43 Million USD | -1.92% |
| 2022 Q3 | 6.14 Million USD | -4.51% |
| 2022 FY | 6.45 Million USD | -8.29% |
| 2022 Q1 | 6.55 Million USD | -6.75% |
| 2022 Q4 | 6.45 Million USD | 5.01% |
| 2021 FY | 7.03 Million USD | 0.0% |
| 2021 Q3 | 6.71 Million USD | 66.58% |
| 2021 Q4 | 7.03 Million USD | 4.7% |
| 2021 Q2 | 4.03 Million USD | 125.43% |
| 2021 Q1 | 1.78 Million USD | 0.0% |
| 2020 Q3 | 1.63 Million USD | -86.36% |
| 2020 Q1 | 13.15 Million USD | 2.76% |
| 2020 Q2 | 11.95 Million USD | -9.14% |
| 2019 FY | 13.15 Million USD | 85.66% |
| 2019 Q4 | 12.79 Million USD | 1.81% |
| 2019 Q3 | 12.57 Million USD | 22.79% |
| 2019 Q1 | 7.08 Million USD | -11.44% |
| 2019 Q2 | 10.23 Million USD | 44.52% |
| 2018 Q3 | 12.82 Million USD | -43.92% |
| 2018 Q4 | 7.99 Million USD | -37.65% |
| 2018 Q1 | 587 Thousand USD | 213.76% |
| 2018 Q2 | 22.87 Million USD | 3797.44% |
| 2018 FY | 7.08 Million USD | 1106.81% |
| 2017 Q1 | 47.28 Million USD | 5.63% |
| 2017 FY | 587 Thousand USD | -98.76% |
| 2017 Q4 | -516 Thousand USD | -100.98% |
| 2017 Q2 | 54.38 Million USD | 15.02% |
| 2017 Q3 | 52.6 Million USD | -3.27% |
| 2016 Q1 | 19.6 Million USD | 69.77% |
| 2016 Q4 | 44.76 Million USD | 30.65% |
| 2016 Q3 | 34.26 Million USD | 49.3% |
| 2016 Q2 | 22.94 Million USD | 17.04% |
| 2016 FY | 47.28 Million USD | 141.15% |
| 2015 Q3 | 1.11 Million USD | 120.47% |
| 2015 Q2 | -5.43 Million USD | -119.06% |
| 2015 FY | 19.6 Million USD | -31.27% |
| 2015 Q1 | 28.52 Million USD | 17.63% |
| 2015 Q4 | 11.54 Million USD | 937.65% |
| 2014 Q1 | 25.87 Million USD | 3.03% |
| 2014 FY | 28.52 Million USD | 10.23% |
| 2014 Q3 | 22.63 Million USD | -15.25% |
| 2014 Q2 | 26.7 Million USD | 3.2% |
| 2014 Q4 | 24.25 Million USD | 7.15% |
| 2013 FY | 25.87 Million USD | 179.94% |
| 2013 Q1 | 9.24 Million USD | 41.8% |
| 2013 Q2 | 23.69 Million USD | 156.32% |
| 2013 Q3 | 25.04 Million USD | 5.71% |
| 2013 Q4 | 25.11 Million USD | 0.28% |
| 2012 FY | 9.24 Million USD | 222.24% |
| 2012 Q1 | -7.56 Million USD | 41.6% |
| 2012 Q2 | -1.44 Million USD | 80.84% |
| 2012 Q3 | 1.04 Million USD | 171.91% |
| 2012 Q4 | 6.51 Million USD | 525.62% |
| 2011 Q4 | -12.94 Million USD | -332.03% |
| 2011 Q1 | -4.78 Million USD | 37.34% |
| 2011 Q3 | -2.99 Million USD | 59.51% |
| 2011 Q2 | -7.4 Million USD | -54.67% |
| 2011 FY | -7.56 Million USD | -58.04% |
| 2010 Q2 | -15.19 Million USD | -234.37% |
| 2010 Q4 | -7.63 Million USD | 32.85% |
| 2010 Q1 | -4.54 Million USD | 42.97% |
| 2010 FY | -4.78 Million USD | -5.3% |
| 2010 Q3 | -11.37 Million USD | 25.15% |
| 2009 Q3 | 1.32 Million USD | 153.57% |
| 2009 FY | -4.54 Million USD | 20.16% |
| 2009 Q4 | -7.96 Million USD | -700.4% |
| 2009 Q2 | -2.47 Million USD | 56.48% |
| 2009 Q1 | -5.69 Million USD | -240.78% |
| 2008 FY | -5.69 Million USD | -158.24% |
| 2008 Q4 | 4.04 Million USD | -4.08% |
| 2008 Q3 | 4.21 Million USD | -52.68% |
| 2008 Q2 | 8.9 Million USD | -8.86% |
| 2008 Q1 | 9.77 Million USD | -14.51% |
| 2007 FY | 9.77 Million USD | -23.5% |
| 2007 Q4 | 11.43 Million USD | 4.51% |
| 2007 Q2 | 15.76 Million USD | 23.39% |
| 2007 Q1 | 12.77 Million USD | -8.35% |
| 2007 Q3 | 10.93 Million USD | -30.61% |
| 2006 Q2 | -1.27 Million USD | 53.52% |
| 2006 Q1 | -2.73 Million USD | -25.1% |
| 2006 FY | 12.77 Million USD | 566.67% |
| 2006 Q4 | 13.93 Million USD | 15763.16% |
| 2006 Q3 | -88.99 Thousand USD | 93.01% |
| 2005 Q1 | -6.65 Million USD | -0.32% |
| 2005 Q4 | -2.18 Million USD | 65.37% |
| 2005 FY | -2.73 Million USD | 58.85% |
| 2005 Q2 | -6.3 Million USD | 5.16% |
| 2005 Q3 | -6.31 Million USD | -0.15% |
| 2004 Q1 | -155.72 Thousand USD | 89.69% |
| 2004 FY | -6.65 Million USD | -4172.27% |
| 2004 Q4 | -6.63 Million USD | -1820.23% |
| 2004 Q3 | -345.35 Thousand USD | -58.42% |
| 2004 Q2 | -217.99 Thousand USD | -39.99% |
| 2003 Q3 | -217 Thousand USD | 38.22% |
| 2003 Q2 | -351.26 Thousand USD | 39.76% |
| 2003 Q4 | -1.5 Million USD | -595.73% |
| 2003 FY | -155.72 Thousand USD | 73.3% |
| 2003 Q1 | -583.13 Thousand USD | 39.82% |
| 2002 Q3 | -238.55 Thousand USD | 0.56% |
| 2002 Q4 | -968.92 Thousand USD | -306.17% |
| 2002 Q1 | -273.37 Thousand USD | 0.0% |
| 2002 Q2 | -239.89 Thousand USD | 12.25% |
| 2002 FY | -583.13 Thousand USD | -169.51% |
| 2001 FY | -216.36 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 492542.748% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -14.21% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 84.925% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 2684.328% |
| Rebus Holdings, Inc. | 305 Thousand USD | -2015.082% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 202.323% |
| Qrons Inc. | 351.42 Thousand USD | -1735.659% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -936.532% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 85.148% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 31710.153% |
| Skye Bioscience, Inc. | -5.72 Million USD | 212.752% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 59.075% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -56.653% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1505.329% |
| SQZ Biotechnologies Company | -36.23 Million USD | 117.802% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -187.704% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -595.761% |
| Mesoblast Limited | 55.85 Million USD | 88.451% |
| Marizyme, Inc. | 18.56 Million USD | 65.259% |
| Genus plc | 190.6 Million USD | 96.615% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -188.528% |
| Pharming Group N.V. | 109.8 Million USD | 94.125% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -649.906% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -431.433% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -848.676% |
| ContraFect Corporation | -6.02 Million USD | 207.053% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -4691.331% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -458.321% |
| IMV Inc. | 7.67 Million USD | 15.899% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -17.25% |
| MultiCell Technologies, Inc. | 90.04 USD | -7164493.514% |
| ONE Bio Corp. | 9.04 Million USD | 28.64% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 978.909% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 50.17% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -371.574% |
| Q BioMed Inc. | 4.06 Million USD | -58.891% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 78.887% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -540.161% |
| Biomind Labs Inc. | 711.4 Thousand USD | -806.801% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 89.345% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -222.648% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 49.627% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1693.389% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -4514.317% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -32370.932% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -192.963% |
| GB Sciences, Inc. | 1.74 Million USD | -269.195% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 3610.022% |
| HST Global, Inc. | 96.79 Thousand USD | -6564.738% |
| CSL Limited | 10.52 Billion USD | 99.939% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -3028.258% |
| Halberd Corporation | 144.72 Thousand USD | -4357.542% |
| Enzolytics Inc. | 981.65 Thousand USD | -557.155% |
| Agentix Corp. | 37.63 Thousand USD | -17042.781% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1058.417% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.318% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 113.722% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 8.768% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -138.166% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 172.976% |
| AVAX Technologies, Inc. | -5.9 Million USD | 209.28% |
| Zenith Capital Corp. | 10.06 Thousand USD | -63999.762% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.608% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -3118.548% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -170.365% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -3821.366% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 35316.727% |
| Kadimastem Ltd | -253.1 Thousand USD | 2648.775% |
| Helix BioMedix, Inc. | -2.57 Million USD | 351.009% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 68.184% |
| BioStem Technologies, Inc. | 4.47 Million USD | -44.253% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -3105.402% |
| LadRx Corporation | -2.03 Million USD | 416.774% |
| Cell Source, Inc. | 9.23 Million USD | 30.123% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -915.638% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -915.638% |
| NovAccess Global Inc. | 2.17 Million USD | -196.126% |
| Affymax, Inc. | -5.59 Million USD | 215.258% |
| Itoco Inc. | 228.3 Thousand USD | -2725.606% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -4643.766% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -30.139% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1232.213% |
| CytoDyn Inc. | 20.26 Million USD | 68.162% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 997163.369% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 69702.539% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 16.286% |
| SYBLEU INC | 473.71 Thousand USD | -1261.792% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -44.738% |
| International Stem Cell Corporation | 2.59 Million USD | -149.073% |
| Bioxytran, Inc. | 1.89 Million USD | -239.72% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -10235.988% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -195.795% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -87.857% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 24.576% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -734.965% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 616.08% |
| Neutra Corp. | 52.18 Thousand USD | -12261.316% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 359.18% |
| PureTech Health plc | -167.19 Million USD | 103.858% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 2734.05% |
| IXICO plc | -4.44 Million USD | 245.143% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 51.199% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 88.239% |
| CSL Limited | 10.52 Billion USD | 99.939% |
| Cellectis S.A. | -43.81 Million USD | 114.722% |